Ryne Biotechnology, a San Diego, CA-based therapeutics company leveraging induced pluripotent stem cell (iPSC) technology to cure neurological disorders, received a $4M award from California Institute for Regenerative Medicine (CIRM).
Led by Nick Manusos, Chief Executive Officer, and Howard Federoff, M.D., Ph.D., Chief Medical Officer, Ryne Bio is a biotechnology company pioneering next-generation approaches to cure neurological disorders. The company utilizes induced pluripotent stem cell (iPSC) technology, which enables scientists to manufacture any human cell, in order to advance its off-the-shelf neuron replacement therapeutics.
The company intends to use the funds to advance its lead candidate RNDP-001, an iPSC-derived dopamine neuron progenitor for the treatment of both inherited and idiopathic forms of Parkinson’s disease, through submission of an Investigational New Drug (IND) application within the next 12 months. RNDP-001 has completed preclinical efficacy and safety studies. This CIRM award will allow Ryne Bio to finalize its IND-package including the production of GMP-grade materials to enable the evaluation of RNDP-001 in Phase 1 clinical trials for both inherited and idiopathic forms of Parkinson’s disease.
Beyond RNDP-001, Ryne Bio is developing a platform of drug candidates, including next-generation, gene-modified programs that have the potential to modify and reverse disease progression in Parkinson’s disease and other moderate to severe central nervous system disorders.
In addition to funding from CIRM, the company was launched and seeded in 2022 by Saisei Ventures, an emerging venture capital firm focused on building revolutionary advanced medicine companies.
FinSMEs
14/02/2023